Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | OGG1 | O15527 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18340892 | 0.91 | L3MBTL1 (0.50) | LMNAL3MBTL1ALDH1A1KDM4EMAPK1 | |
| SCHEMBL13918097 | 0.84 | L3MBTL1 (0.53) | LMNAL3MBTL1ALDH1A1KDM4EMAPK1 | |
| SCHEMBL17952793 | 0.83 | HSD17B3 (0.56) | LMNAL3MBTL1ALDH1A1OGG1TDP1 | |
| SCHEMBL3844203 | 0.83 | HSD17B3 (0.56) | LMNAL3MBTL1ALDH1A1OGG1TDP1 | |
| SCHEMBL3896481 | 0.82 | OGG1 (0.58) | LMNAL3MBTL1ALDH1A1OGG1KDM4E | |
| SCHEMBL4889161 | 0.82 | CES2 (0.56) | ALDH1A1PARP1TDP1NPC1RAB9A | |
| SCHEMBL7243792 | 0.81 | HDAC1 (0.63) | L3MBTL1ALDH1A1HPGDHDAC1MEN1 | |
| SCHEMBL6336402 | 0.80 | TDP1 (0.68) | LMNAL3MBTL1KDM4EMAPK1HPGD | |
| SCHEMBL25169970 | 0.80 | HDAC1 (0.66) | LMNAL3MBTL1ALDH1A1HPGDTDP1 | |
| SCHEMBL3604586 | 0.80 | PARP1 (0.49) | LMNAL3MBTL1ALDH1A1OGG1PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1215203-B1 | HYDROXAMIC ACID DERIVATIVES, PROCESS FOR THE PRODUCTION THEREOF AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2005-02-16 | — | — | EP | disclosed |
| US-20040214896-A1 | Hydroxamic acid derivatives, the methods for preparation thereof and pharmaceutical compositions comprising thereof, as an active ingredient | ONO PHARMACEUTICAL CO., LTD. | 2004-10-28 | — | — | US | disclosed |
| US-6770644-B1 | Hydroxamic acid derivatives, process for the production thereof and drug containing the same as the active ingredient | ONO PHARMACEUTICALS CO., LTD. (JP) | 2004-08-03 | — | — | US | disclosed |
| EP-1215203-A1 | HYDROXAMIC ACID DERIVATIVES, PROCESS FOR THE PRODUCTION THEREOF AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214896-A1 | Hydroxamic acid derivatives, the methods for preparation thereof and pharmaceutical compositions comprising thereof, as an active ingredient | HIF1AN, IL6, PYGM | LMNA 714/4885L3MBTL1 1777/4885ALDH1A1 274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.